2022 Regulators, industry and academics paving new paths for clinical cancer research with health care impact
The IBCD 2022 edition tackles the difficult questions in drug and biomarker development, and will explore answers to the burning questions still out there.
• To what extent is Whole Genome Sequencing a hype or does it have real value for health care settings?
• Will Real-World data challenge classical trial designs?
• Aren’t we fooled by biased biomarker-statistics in biomarker-driven trials?
• Are Laboratory-Developed test a good alternative to regulatory-approved assays?
This and much more will be tackled with regulatory science experts, scientists, clinicians, pathologists, and payers at the next IBCD Conference, to be held in Barcelona, Spain.